Stimulatory Effects of Soluplus® on Flufenamic Acid β-Cyclodextrin Supramolecular Complex: Physicochemical Characterization and Pre-clinical Anti-inflammatory Assessment

被引:21
作者
Alshehri, Sultan [1 ,2 ]
Imam, Syed Sarim [1 ]
Altamimi, Mohammad A. [1 ]
Hussain, Afzal [1 ]
Shakeel, Faiyaz [1 ]
Alshehri, Abdulhakeem [3 ]
机构
[1] King Saud Univ, Coll Pharm, Dept Pharmaceut, POB 2457, Riyadh, Saudi Arabia
[2] Al Marefa Univ, Coll Pharm, Riyadh, Saudi Arabia
[3] King Abdulaziz Air Base Hosp, Minist Def, Pharm, Dhahran, Saudi Arabia
关键词
flufenamic acid; inclusion complex; anti-inflammatory activity; solubility enhancement; Soluplus (R); HOT-MELT EXTRUSION; INCLUSION COMPLEX; DISSOLUTION BEHAVIOR; SOLID DISPERSIONS; L-ARGININE; SOLUBILITY; DRUG; DELIVERY; SYSTEMS; ENHANCEMENT;
D O I
10.1208/s12249-020-01684-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The present study demonstrates the solubility and dissolution of flufenamic acid (FLF)/beta-cyclodextrin (beta-CD)/Soluplus (R) supramolecular ternary inclusion complex. The binary and ternary inclusion complexes were prepared using solvent evaporation and the microwave irradiation method. The prepared inclusion complexes were evaluated for physicochemical characterization and anti-inflammatory activity using a murine paw edema mol. The phase solubility studies demonstrated 4.59-fold and 17.54-fold enhancements in FLF solubility with beta-CD alone and beta-CD:Soluplus (R) combination compared with pure FLF, respectively. The in vitro drug release results revealed a significant improvement (P < 0.05) in the release pattern compared with pure FLF. Maximum release was found with flufenamic acid binary and ternary complexes prepared using the microwave irradiation method, i.e., 75.23 +/- 3.12% and 95.36 +/- 3.23% in 60 min, respectively. The physicochemical characterization results showed complex formation and conversion of the crystalline form of FLF to an amorphous form. The SEM study revealed the presence of a more agglomerated and amorphous structure of the solid particles, which confirmed the formation of complexes. The anti-inflammatory effect of the complex was higher than pure FLF. Therefore, the FLF:beta-CD:Soluplus (R) inclusion complex may be a very valuable formulation with improved solubility, dissolution, and anti-inflammatory effect.
引用
收藏
页数:13
相关论文
共 47 条
[1]  
Abignente E., 1982, Anal. Profiles Drug Subst, V11, P313
[2]   Host-guest complex of β-cyclodextrin and pluronic F127 with Luteolin: Physicochemical characterization, anti-oxidant activity and molecular modeling studies [J].
Alshehri, Sultan ;
Imam, Syed Sarim ;
Altamimi, Mohammad A. ;
Jafar, Mohammed ;
Hassan, Mohd Zaheen ;
Hussain, Afzal ;
Ahad, Abdul ;
Mandi, Wael .
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2020, 55
[3]   Rat palatability, pharmacodynamics effect and bioavailability of mefenamic acid formulations utilizing hot-melt extrusion technology [J].
Alshehri, Sultan ;
Shakeel, Faiyaz ;
Elzayat, Ehab ;
Almeanazel, Osaid ;
Altamimi, Mohammad ;
Shazly, Gamal ;
Kazi, Mohsin ;
Almutairy, Bjad ;
Alsulays, Bader ;
Alshetaili, Abdullah ;
Alalaiwe, Ahmed ;
Repka, Michael .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2019, 45 (10) :1610-1616
[4]   Solubility measurement, thermodynamics and molecular interactions of flufenamic acid in different neat solvents [J].
Alshehri, Sultan ;
Shakeel, Faiyaz .
JOURNAL OF MOLECULAR LIQUIDS, 2017, 240 :447-453
[5]   Influence of the microwave technology on solid dispersions of mefenamic acid and flufenamic acid [J].
Alshehri, Sultan ;
Shakeel, Faiyaz ;
Ibrahim, Mohamed ;
Elzayat, Ehab ;
Altamimi, Mohammad ;
Shazly, Gamal ;
Mohsin, Kazi ;
Alkholief, Musaed ;
Alsulays, Bader ;
Alshetaili, Abdullah ;
Alshahrani, Abdulaziz ;
Almalki, Bander ;
Alanazi, Fars .
PLOS ONE, 2017, 12 (07)
[6]   α-Lipoic Acid in Soluplus® Polymeric Nanomicelles for Ocular Treatment of Diabetes-Associated Corneal Diseases [J].
Alvarez-Rivera, Fernando ;
Fernandez-Villanueva, David ;
Concheiro, Angel ;
Alvarez-Lorenzo, Carmen .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 105 (09) :2855-2863
[7]  
Aronson J.K., 2009, Meyler's Side Effects ofAnalgesics and Anti-Inflammatory Drugs, V15th
[8]  
Badran M, 2014, DIG J NANOMATER BIOS, V9, P83
[9]   Controlled-release nanoencapsulating microcapsules to combat inflammatory diseases [J].
Baek, Jong-Suep ;
Yeo, Eng Wan ;
Lee, Yin Hao ;
Tan, Nguan Soon ;
Loo, Say Chye Joachim .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 :1707-1717
[10]   Development and Validation of a Discriminating In Vitro Dissolution Method for a Poorly Soluble Drug, Olmesartan Medoxomil: Comparison Between Commercial Tablets [J].
Bajerski, Lisiane ;
Rossi, Rochele Cassanta ;
Dias, Carolina Lupi ;
Bergold, Ana Maria ;
Froehlich, Pedro Eduardo .
AAPS PHARMSCITECH, 2010, 11 (02) :637-644